Shanghai Fosun Pharmaceutical Stock Working Capital
| SFOSFDelisted Stock | USD 1.70 0.00 0.00% |
Shanghai Fosun Pharmaceutical fundamentals help investors to digest information that contributes to Shanghai Fosun's financial success or failures. It also enables traders to predict the movement of Shanghai Pink Sheet. The fundamental analysis module provides a way to measure Shanghai Fosun's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Fosun pink sheet.
Shanghai |
Shanghai Fosun Pharmaceutical Company Working Capital Analysis
Shanghai Fosun's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Shanghai Fosun Working Capital | (817 M) |
Most of Shanghai Fosun's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Shanghai Fosun Pharmaceutical has a Working Capital of (817 Million). This is 291.94% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The working capital for all United States stocks is 155.27% higher than that of the company.
Shanghai Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in working capital category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 39.01 B | |||
| Gross Profit | 18.71 B | |||
| EBITDA | 8.71 B | |||
| Net Income | 4.74 B | |||
| Cash And Equivalents | 14.64 B | |||
| Cash Per Share | 5.49 X | |||
| Total Debt | 9.05 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 16.30 X | |||
| Cash Flow From Operations | 3.95 B | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 36.28 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 12.25 B | |||
| Total Asset | 93.29 B | |||
| Retained Earnings | 10.37 B | |||
| Working Capital | (817 M) | |||
| Current Asset | 10.27 B | |||
| Current Liabilities | 11.09 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 93.29 B | |||
| Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |